QNRX Quoin Pharmaceuticals, Ltd.
Price Chart
Executive Summary
LUCID CAPITAL MARKETS initiated coverage on Quoin Pharmaceuticals (QNRX) with a Buy rating and a $30 price target, implying 558% upside from the current $4.56 close. The firm joins a heavily bullish consensus — 8 of 9 analysts rate the stock Buy or Strong Buy, with only one Hold. The mean price target is $29.75, median $32.50, high $40, low $14. LUCID's $30 target sits near the consensus mean, indicating alignment with the Street's optimistic view. However, LUCID's track record is weak — just 36% accuracy on 22 calls — which tempers the signal's credibility. No recent upgrades or downgrades exist in the 30-day window, and EPS estimates have been revised upward for the current fiscal year (one revision up in the last 7 days). Institutional activity shows a new $43.3M position from Morgan Stanley, while UBS nearly exited. Short interest is elevated at 56.7% of float, creating a potential squeeze catalyst if the bullish thesis gains traction. Bottom line: a high-upside initiation from a low-accuracy firm, best treated as confirmatory rather than a standalone catalyst.
Impact Score
Consensus & Targets
The consensus is heavily bullish: 2 Strong Buy, 6 Buy, 1 Hold, 0 Sell, 0 Strong Sell across 9 analysts. That is 89% Buy/Strong Buy, 11% Hold, 0% Sell. The direction is overwhelmingly positive, with no bearish voices.
Mean PT is $29.75, median $32.50, high $40, low $14. Current price $4.56 implies 552% upside to the mean. LUCID's $30 target is slightly above the mean ($29.75) and below the median ($32.50), placing it in the middle of the consensus range.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-05-04 | LUCID CAPITAL MARKETS | initiate | Buy | — |
| 2024-03-15 | Maxim Group | maintain | Buy | $4.00 |
No upgrades or downgrades in the last 30 days. EPS revisions show one upward revision for the current fiscal year (0y) in the last 7 days, while estimates for the current quarter (0q) and next quarter (+1q) have been revised lower over the past 30 days. Overall, estimates are mixed but slightly positive for the annual period.
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0q | $-1.61 | $-1.61 — $-1.61 | $0.00 | ↑0 ↓0 |
| +1q | $-1.32 | $-1.32 — $-1.32 | $0.00 | ↑0 ↓0 |
| +1y | $-3.90 | $-3.90 — $-3.90 | $0.00 | ↑0 ↓0 |
| 0y | $-5.85 | $-5.85 — $-5.85 | $0.00 | ↑1 ↓0 |
Cross-Platform Signals
Insider trades: none reported. Congressional trades: none. Institutional activity: Morgan Stanley opened a new $43.3M position (bullish signal), while UBS nearly exited (-99.2% to $7K, bearish). Short interest is 56.7% of float, extremely high — this creates a potential squeeze dynamic if the bullish thesis gains momentum. The Morgan Stanley entry and high short interest converge with the bullish analyst signal, while the UBS exit diverges.
Actionable Insight
The initiation adds a bullish voice to an already crowded consensus, but LUCID's low accuracy (36%) limits conviction. Traders should watch for additional institutional buying or a short squeeze catalyst — the 56.7% short interest is the most actionable data point here.
Documents Analyzed
Report based on filing metadata.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
10d ago
|
ANALYST-UPGRADE
| $6.36 $4.56 | ▼ −28.30% | ▼ −34.08% | $4.20 (−33.96%) |
|
May 7, 2026
5w ago
|
Press Release
| $6.37 $4.43 | ▼ −30.46% | ▼ −33.59% | $4.20 (−34.07%) |
|
May 5, 2026
5w ago
|
ANALYST-UPGRADE
| $6.31 $4.56 | ▼ −27.73% | ▼ −32.69% | $4.20 (−33.44%) |
|
Apr 30, 2026
6w ago
|
Press Release
| $6.48 $4.94 | ▼ −23.77% | ▼ −28.73% | $4.20 (−35.19%) |
|
Mar 19, 2026
12w ago
|
Press Release
| $8.26 $6.46 | ▼ −21.79% | ▼ −29.41% | $4.20 (−49.15%) |
|
Mar 11, 2026
13w ago
|
8-K
| $8.09 $5.90 | ▼ −27.07% | ▼ −29.05% | $4.20 (−48.08%) |
|
Mar 11, 2026
13w ago
|
Press Release
| $8.49 $5.74 | ▼ −32.39% | ▼ −32.91% | $4.20 (−50.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access